HC Wainwright Issues Positive Outlook for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.17) for the quarter, up from their prior forecast of ($0.20). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.49) EPS.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. TScan Therapeutics had a negative return on equity of 73.32% and a negative net margin of 1,256.81%.The business had revenue of $2.57 million during the quarter.

TCRX has been the topic of a number of other reports. Wedbush upped their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Finally, Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, TScan Therapeutics has a consensus rating of “Hold” and an average price target of $6.20.

TScan Therapeutics Trading Up 4.6%

NASDAQ:TCRX opened at $1.13 on Friday. TScan Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The stock has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.40. The stock has a market capitalization of $64.13 million, a price-to-earnings ratio of -1.13 and a beta of 1.03.

Institutional Trading of TScan Therapeutics

Large investors have recently modified their holdings of the business. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics in the fourth quarter worth $25,000. HRT Financial LP purchased a new stake in TScan Therapeutics during the 4th quarter worth about $26,000. Catalyst Funds Management Pty Ltd acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $26,000. Quadrature Capital Ltd acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $33,000. Finally, Boothbay Fund Management LLC boosted its stake in shares of TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the company’s stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the acquisition, the insider owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. The trade was a 1.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 161,801 shares of company stock worth $145,621. Company insiders own 4.35% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.